Distinguished in Primitive Neuroectodermal Tumor (PNET)

Dr. Parvin F. Peddi

Oncology
Providence
2121 Santa Monica Boulevard, Garden Level, 
Santa Monica, CA 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth

Distinguished in Primitive Neuroectodermal Tumor (PNET)
Providence
2121 Santa Monica Boulevard, Garden Level, 
Santa Monica, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Parvin Peddi is an Oncologist in Santa Monica, California. Dr. Peddi is rated as a Distinguished provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Angiosarcoma, and Inflammatory Breast Cancer. Dr. Peddi is currently accepting new patients.

Her clinical research consists of co-authoring 21 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Licenses
Internal Medicine in CA
Hospital Affiliations
Saint John's Health Center
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Nippon Life
  • INSURANCE PLAN
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

2121 Santa Monica Boulevard, Garden Level, Santa Monica, CA 90404
Call: 310-582-7100

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


6 Clinical Trials

A Phase Ib/III Study to Evaluate the Efficacy and Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer Who Failed Standard of Care Therapies
A Phase Ib/III Study to Evaluate the Efficacy and Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer Who Failed Standard of Care Therapies
Enrollment Status: Recruiting
Publish Date: September 16, 2025
Intervention Type: Drug
Study Drug: Afuresertib
Study Phase: Phase 3
The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and Tucatinib
The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and Tucatinib
Enrollment Status: Active_not_recruiting
Publish Date: October 29, 2025
Intervention Type: Other, Biological, Drug
Study Drugs: Trastuzumab Emtansine, Tucatinib
Study Phase: Phase 3
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
Enrollment Status: Terminated
Publish Date: July 15, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients With HER2-Negative Breast Cancer and Brain Metastases
A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients With HER2-Negative Breast Cancer and Brain Metastases
Enrollment Status: Active_not_recruiting
Publish Date: April 24, 2025
Intervention Type: Biological
Study Drug: Sacituzumab Govitecan
Study Phase: Phase 2
A Phase 1 First-in-Human Dose Study of LY3023414 in Patients With Advanced Cancer
A Phase 1 First-in-Human Dose Study of LY3023414 in Patients With Advanced Cancer
Enrollment Status: Completed
Publish Date: April 08, 2022
Intervention Type: Drug
Study Drugs: LY3023414, Midazolam, Fulvestrant, Pemetrexed, Cisplatin, Abemaciclib, Letrozole
Study Phase: Phase 1
Phase II Randomized Trial of Mugard Compared With Best Supportive Care for Prevention and Treatment of Stomatitis in Women With Hormone Receptor Positive Breast Cancer Initiating Treatment With Everolimus-based Endocrine Therapy.
Phase II Randomized Trial of Mugard Compared With Best Supportive Care for Prevention and Treatment of Stomatitis in Women With Hormone Receptor Positive Breast Cancer Initiating Treatment With Everolimus-based Endocrine Therapy.
Enrollment Status: Completed
Publish Date: September 21, 2020
Intervention Type: Drug, Other
Study Phase: Phase 2
View 5 Less Clinical Trials

21 Total Publications

AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer.
AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 22, 2023
View All 21 Publications
Similar Doctors
Distinguished in Primitive Neuroectodermal Tumor (PNET)
Dr. Jana L. Portnow
Oncology
Distinguished in Primitive Neuroectodermal Tumor (PNET)
Dr. Jana L. Portnow
Oncology

City Of Hope Medical Foundation

209 Fair Oaks Ave, 
South Pasadena, CA 
 (19.9 miles away)
626-396-2900
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jana Portnow is an Oncologist in South Pasadena, California. Dr. Portnow is rated as a Distinguished provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). Her top areas of expertise are Astrocytoma, Glioblastoma, Glioma, Brain Tumor, and Endoscopy.

Distinguished in Primitive Neuroectodermal Tumor (PNET)
Dr. Ronald B. Natale
Oncology
Distinguished in Primitive Neuroectodermal Tumor (PNET)
Dr. Ronald B. Natale
Oncology
8700 Beverly Blvd, #ac1042b, 
West Hollywood, CA 
 (6.4 miles away)
310-423-1101
Languages Spoken:
English
See accepted insurances

Ronald Natale is an Oncologist in West Hollywood, California. Dr. Natale is rated as a Distinguished provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Pleuropulmonary Blastoma, Small Cell Lung Cancer (SCLC), and Tissue Biopsy.

Distinguished in Primitive Neuroectodermal Tumor (PNET)
Dr. Surasak Phuphanich
Neurology | Oncology
Distinguished in Primitive Neuroectodermal Tumor (PNET)
Dr. Surasak Phuphanich
Neurology | Oncology
8700 Beverly Blvd, 
West Hollywood, CA 
 (6.4 miles away)
310-423-5000
Languages Spoken:
English
See accepted insurances

Surasak Phuphanich is a Neurologist and an Oncologist in West Hollywood, California. Dr. Phuphanich is rated as an Elite provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). His top areas of expertise are Glioblastoma, Astrocytoma, Glioma, and Gliosarcoma.

VIEW MORE PRIMITIVE NEUROECTODERMAL TUMOR (PNET) DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Peddi's expertise for a condition
ConditionClose
    • Distinguished
    • Angiosarcoma
      Dr. Peddi is
      Distinguished
      . Learn about Angiosarcoma.
      See more Angiosarcoma experts
    • Breast Cancer
      Dr. Peddi is
      Distinguished
      . Learn about Breast Cancer.
      See more Breast Cancer experts
    • Inflammatory Breast Cancer
      Dr. Peddi is
      Distinguished
      . Learn about Inflammatory Breast Cancer.
      See more Inflammatory Breast Cancer experts
    • Paget Disease of the Breast
      Dr. Peddi is
      Distinguished
      . Learn about Paget Disease of the Breast.
      See more Paget Disease of the Breast experts
    • Posterior Fossa Tumor
      Dr. Peddi is
      Distinguished
      . Learn about Posterior Fossa Tumor.
      See more Posterior Fossa Tumor experts
    • Primitive Neuroectodermal Tumor (PNET)
      Dr. Peddi is
      Distinguished
      . Learn about Primitive Neuroectodermal Tumor (PNET).
      See more Primitive Neuroectodermal Tumor (PNET) experts
    • Advanced
    • HER-2 Positive Breast Cancer
      Dr. Peddi is
      Advanced
      . Learn about HER-2 Positive Breast Cancer.
      See more HER-2 Positive Breast Cancer experts
    • Triple-Negative Breast Cancer
      Dr. Peddi is
      Advanced
      . Learn about Triple-Negative Breast Cancer.
      See more Triple-Negative Breast Cancer experts
    • Experienced
    • Adrenal Cancer
      Dr. Peddi is
      Experienced
      . Learn about Adrenal Cancer.
      See more Adrenal Cancer experts
    • Agranulocytosis
      Dr. Peddi is
      Experienced
      . Learn about Agranulocytosis.
      See more Agranulocytosis experts
    • ALK-Positive Non-Small Cell Lung Cancer
      Dr. Peddi is
      Experienced
      . Learn about ALK-Positive Non-Small Cell Lung Cancer.
      See more ALK-Positive Non-Small Cell Lung Cancer experts
    • Anal Cancer
      Dr. Peddi is
      Experienced
      . Learn about Anal Cancer.
      See more Anal Cancer experts
    • BRCA Positive Breast Cancer
      Dr. Peddi is
      Experienced
      . Learn about BRCA Positive Breast Cancer.
      See more BRCA Positive Breast Cancer experts
    • Chronic Familial Neutropenia
      Dr. Peddi is
      Experienced
      . Learn about Chronic Familial Neutropenia.
      See more Chronic Familial Neutropenia experts
    View All 36 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2026 All Rights Reserved

      Request an Appointment

      If you are experiencing a medical emergency, call 9-1-1.

      MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

        Close
        0 / 1000

        Please provide us with the below insurance information:

                By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.